Get the Stockscreener App
5.17
0.39%
-0.02
Pre-market:
5.30
0.13
+2.51%
Ataibeckley Inc stock is traded at $5.17, with a volume of 10.12M.
It is down -0.39% in the last 24 hours and up +35.70% over the past month.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
See More
Previous Close:
$5.19
Open:
$5.11
24h Volume:
10.12M
Relative Volume:
1.41
Market Cap:
$1.90B
Revenue:
$4.09M
Net Income/Loss:
$-660.15M
P/E Ratio:
-2.2427
EPS:
-2.3053
Net Cash Flow:
$-117.10M
1W Performance:
+5.94%
1M Performance:
+35.70%
6M Performance:
+30.23%
1Y Performance:
+96.58%
1-Day Range:
$5.01
$5.40
1-Week Range:
$4.77
$5.45
52-Week Range:
$2.53
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
Name
Ataibeckley Inc
Sector
Industry
Phone
1 929 207 2670
Address
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Compare ATAI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
5.17 | 1.90B | 4.09M | -660.15M | -117.10M | -2.3053 |
VRTX
Vertex Pharmaceuticals Inc
|
498.43 | 126.50B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
662.88 | 69.50B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.30 | 56.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
323.50 | 43.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.77 | 40.34B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Deutsche Bank | Buy |
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Ataibeckley Inc Stock (ATAI) Latest News
Form 144 AtaiBeckley Inc. For: 7 July By Investing.com - Investing.com India
[144] AtaiBeckley Inc. SEC Filing - Stock Titan
AtaiBeckley Completes VLS-01 Dosing in Phase IIb Depression Study - The Globe and Mail
ATAI Upgraded by Canaccord Genuity -- Price Target Raised to $17 - GuruFocus
AtaiBeckley set to unlock value from positive depression therapy trial results, says Jefferies - Proactive financial news
CCORF Maintains AtaiBeckley(ATAI.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Canaccord raises Atai Life Sciences stock price target to $17 on MDD plans - Investing.com
AtaiBeckley (ATAI) Stock Could Be Overvalued Following Phase 2b Dosing Update - Yahoo Finance
AtaiBeckley | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
AtaiBeckley (ATAI) Draws Takeover Talk From A Major U.S. Drugmaker - Yahoo Finance
Did AtaiBeckley’s (ATAI) FTSE Russell Index Additions and BPL-003 Milestone Just Recast Its Investment Narrative? - webull.com
What AtaiBeckley (ATAI)'s Elumina Last-Patient Dosed Milestone Means For Shareholders - Yahoo Finance
AtaiBeckley (ATAI) Faces Takeover Speculation Amid Stock Fluctua - GuruFocus
AtaiBeckley completes dosing in VLS-01 depression trial - Investing.com UK
AtaiBeckley completes dosing in VLS-01 depression trial By Investing.com - Investing.com Australia
Small cap wrap: Graphene Manufacturing Group, Grey Matter Health, AtaiBeckley… - Proactive financial news
AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder - Investing News Network
AtaiBeckley Announces Last Patient Dosed in Phase 2b Elumina Trial of VLS-01 for Treatment-Resistant Depression; Topline Data Expected in Q4 2026 - Quiver Quantitative
AtaiBeckley ends dosing in VLS-01 depression trial, eyes Phase 3 - Stock Titan
AtaiBeckley completes dosing in Phase 2b depression trial, expects topline data in Q4 - Proactive financial news
ATAIAtaiBeckley Inc Volatility & Greeks - Finviz
AtaiBeckley (ATAI) Advances BPL 003 Into Phase III For Treatment Resistant Depression - Sahm
AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026 - The Globe and Mail
AtaiBeckley Reflects a New Push for Rapid-Acting Mental Health Drugs - The Globe and Mail
Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026? - Yahoo Finance
ATAI Q1 2026 Earnings: Narrower-than-expected loss per share, stock dips 3%Investor Earnings Call - dars.gov.et
AtaiBeckley: BPL-003's Promising Potential On TRD Keeps Me Bullish (NASDAQ:ATAI) - Seeking Alpha
Ataibeckley CMO Craig James sells $192,031 of company stock - Investing.com UK
Ataibeckley COO Gerd Kochendoerfer sells $250,000 in stock - Investing.com UK
Ataibeckley COO Gerd Kochendoerfer sells $250,000 in stock By Investing.com - Investing.com Nigeria
AtaiBeckley Inc. (ATAI) CMO sells shares after exercising stock options - Stock Titan
Ataibeckley CMO Craig James sells $192,031 of company stock By Investing.com - Investing.com South Africa
Form 4 ATAI Beckley Inc For: 29 June By Investing.com - Investing.com South Africa
Planned options exercise and 50K-share sale by AtaiBeckley (ATAI) COO - Stock Titan
AtaiBeckley Inc.(NasdaqGM: ATAI) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
AtaiBeckley Inc.(NasdaqGM: ATAI) added to Russell 2500 Growth Benchmark - marketscreener.com
AtaiBeckley Inc.(NasdaqGM: ATAI) added to Russell 2000 Index - marketscreener.com
AtaiBeckley Inc.(NasdaqGM: ATAI) added to Russell 2000 Value Benchmark - marketscreener.com
AtaiBeckley Inc.(NasdaqGM: ATAI) added to Russell 2000 Growth Benchmark - marketscreener.com
AtaiBeckley Inc.(NasdaqGM: ATAI) added to Russell 3000E Growth Benchmark - marketscreener.com
AtaiBeckley Inc.(NasdaqGM: ATAI) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
ATAI Rises As AtaiBeckley Lands Russell Index Upgrade - timothysykes.com
AtaiBeckley Inc.(NasdaqGM: ATAI) added to Russell Small Cap Completeness Index - marketscreener.com
ATAI Jumps As AtaiBeckley Joins Russell 2000 And 3000 - StocksToTrade
ATAI Jumps As AtaiBeckley Lands Russell Index Upgrade - timothysykes.com
Form 144 ATAIBECKLEY INC For: 26 June By Investing.com - Investing.com South Africa
JonesTrading Maintains AtaiBeckley(ATAI.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Does AtaiBeckley’s (ATAI) Russell Inclusion Reframe Its Mental Health Pipeline as a Core Benchmark Story? - simplywall.st
Ataibeckley Inc Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.27%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):